DFY.TO 0.66AGF.B.TO 0.05CDR.TO 0.33BLX -0.69KINS 0.34MCY -1.24DIS -2.04ATD.TO 0.6
AbbVie Inc. (ABBV)

NYSE:ABBV

AbbVie Inc. (ABBV)

254.49
+0.10 (0.04%)
as of Jul 17, 2026, 8:00:00 pm Market Open.
333 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJul 18, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

AbbVie Inc. has shown a strong resilience in its growth trajectory, with experts highlighting a 7% earnings growth and projected revenue growth of 24%. Despite the loss of revenue from Humira, the company has successfully introduced new drugs and made acquisitions to fill the gap. Analysts are optimistic, pointing to a solid drug pipeline, including Rinvoq, which has shown a year-over-year growth of 40%. The stock is gaining attention for its quality and reduced execution risk, particularly in a selective healthcare sector. Investors appreciate AbbVie's handling of the Humira patent cliff, demonstrating skill in maintaining competitiveness and diversification, while also benefiting from a solid dividend yield.

consensus icon
Consensus
Positive
valuation icon
Valuation
Fair Value
review icon
Similar
AZN
WEAK BUY

AbbVie Inc.(ABBV)

Jun 28, 2022
It's one of the big healthcare stocks, a sector he likes. The issue here is that their big drug is coming off patent this year. Not sure how this will go. Be cautious in the coming year. The stock could be weak. Great dividend and drug pipeline, though.
Photo of Bruce MurrayBruce MurrayUnlock Rating
$152.49

Stock price when the opinion was issued

$254.49

As of Jul 17, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

Jun 17, 2022
Pays a 4% yield and just started working on this Allergen franchise they just bought. Their core drugs keep selling. This will go higher.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$138.28

Stock price when the opinion was issued

$254.49

As of Jul 17, 2026. Market Open.

0
SELL

AbbVie Inc.(ABBV)

Jun 08, 2022
Largest drug going off patent, already seeing bio-similars. Earnings will go dormant.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$149.10

Stock price when the opinion was issued

$254.49

As of Jul 17, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

May 20, 2022
Operates at almost 8% free cash flow yield. Pays a 3.7% yield.
Photo of Jason Snipe, CIO, Odyssey Capital AdvisorsJason Snipe, CIO, Odyssey Capital AdvisorsUnlock Rating
$148.32

Stock price when the opinion was issued

$254.49

As of Jul 17, 2026. Market Open.

0
COMMENT

AbbVie Inc.(ABBV)

May 13, 2022
Biotechs have strong balance sheets, better than a few years ago. Likes this as well as Amgen. Better to buy individual biotech stocks over ETFs. He has options calls on Abbvie.
Photo of Pete NajarianPete Najarian
Owned
Unlock Rating
$153.50

Stock price when the opinion was issued

$254.49

As of Jul 17, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

May 13, 2022
Is an innovative pharma company. Life sciences companies are getting more interest from investors.
Photo of Shannon Saccocia, CIO, Boston PrivateShannon Saccocia, CIO, Boston Private
Owned
Unlock Rating
$153.50

Stock price when the opinion was issued

$254.49

As of Jul 17, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

May 13, 2022
People want cash flow and now cash burn now. Biotech is bouncing like cryptos. You can buy this of IBB, but there are huge opportunities in biotech.
Photo of Bryn TalkingtonBryn Talkington
Owned
Unlock Rating
$153.50

Stock price when the opinion was issued

$254.49

As of Jul 17, 2026. Market Open.

0
PAST TOP PICK

AbbVie Inc.(ABBV)

May 12, 2022
(A Top Pick Oct 20/20, Up 90%) Largest biotech company. Concerns about Humira coming off patent were overblown. Likes its R&D, as well as its M&A strategy. Missed on one trial, another one coming up. Good balance sheet, pretty good dividend, consistent cashflow. Good entry point.
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$152.97

Stock price when the opinion was issued

$254.49

As of Jul 17, 2026. Market Open.

0
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

AbbVie Inc.(ABBV)

May 03, 2022
(A Top Pick Apr 27/21, Up 34.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABBV has triggered its stop at $152. To remain disciplined we recommend covering the position at this time.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$148.74

Stock price when the opinion was issued

$254.49

As of Jul 17, 2026. Market Open.

0
PARTIAL SELL

AbbVie Inc.(ABBV)

Apr 13, 2022
He trimmed his AbbVie to buy back Chipotle which he once owned. Though the near-term market direction is cloudy, he is seeking opportunity. He bought AbbVie last November at $115. Over three days, AbbVie jumped 8%, way faster than in recent years, but then it was wiped out in just three days. So, he sold half his position. He bought Chipotle, because he wanted growth at a reasonable valuation. It can endure theses inflationary times. Brand recognition helps. Fast food continues to sell.
Photo of Joe TerranovaJoe Terranova
Owned
Unlock Rating
$159.00

Stock price when the opinion was issued

$254.49

As of Jul 17, 2026. Market Open.

0
SELL ON STRENGTH

AbbVie Inc.(ABBV)

Apr 12, 2022
Allan Tong’s Discover Picks Though shares are topping $175, AbbVie's PE of 25.1x is at its lowest in the past year, nearly 40x at the end of March 2021, for example. Then again, Merck trades at 18x and Pfizer 13.8x. The street remains confident in AbbVie, calling 11 buys and five holds, though the price target is $155.47, about $15 lower than current levels. AbbVie looks healthy for the long term, but it wouldn't hurt to bank a few profits while shares are riding high. Read 3 Promising Healthcare Stocks for our full analysis.
Photo of Stockchase DiscoverStockchase Discover
Owned
Unlock Rating
$167.31

Stock price when the opinion was issued

$254.49

As of Jul 17, 2026. Market Open.

0
SELL

AbbVie Inc.(ABBV)

Apr 07, 2022
Major product, over 40% of revenues, is going off-patent next year, creating a higher risk profile. He sold. It has risen since then, but he doesn't like to be greedy, and he can sleep better. Sometimes it's time to move on. Wonderful profile, attractive dividend, attractive multiple, good growth rate, momentum.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$173.86

Stock price when the opinion was issued

$254.49

As of Jul 17, 2026. Market Open.

0
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

AbbVie Inc.(ABBV)

Apr 05, 2022
(A Top Pick Apr 22/21, Up 47.9%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABBV is progressing well. We now recommend trailing up the stop (from $140) to $152.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$164.36

Stock price when the opinion was issued

$254.49

As of Jul 17, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

Mar 23, 2022
He likes it. Pays a 3.5% dividend. They are presenting at several big medical conferences, so any good news could spike the stock.
Photo of Jon Nagerian, Co-founder, MarketRebellion.comJon Nagerian, Co-founder, MarketRebellion.com
Owned
Unlock Rating
$158.93

Stock price when the opinion was issued

$254.49

As of Jul 17, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

Mar 23, 2022
She just trimmed her holding last week, because it's done very well. Their drug pipeline looks positive. Healthcare is her second-favourite sector and this is a great way to play it.
Photo of Shannon Saccocia, CIO, Boston PrivateShannon Saccocia, CIO, Boston Private
Owned
Unlock Rating
$158.93

Stock price when the opinion was issued

$254.49

As of Jul 17, 2026. Market Open.

0
Showing 61 to 75 of 177 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NFLX -5.4$68.95
RIO -0.52$90.15
MAR -4.9$366.24
META -18.53$646.01
AMT 1.14$170.06
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

DFY.TO 0.66$78.28
AGF.B.TO 0.05$22.89
CDR.TO 0.33$3.91
BLX -0.69$59.25
KINS 0.34$20.09

Popular Articles

Latest Sell Signals

NFLX -5.4$68.95
NFLX -5.4$68.95
CAT 3.11$880.28
NFLX -5.4$68.95
DOL.TO 1.92$190.87

Most Recent Experts

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Bruce Campbell (2)

Bruce Campbell (2)

Stone Castle Investment Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like